The last three and a half days exhibiting and demonstrating our EECP® Therapy and Biox products at the European Society of Cardiology (ESC) in Barcelona were extremely busy, slightly challenging at times, and very, very rewarding. Attendee traffic at our booth was very good due to a number of factors but especially the pre-show preparation which included setting up key meeting with prospective customers and mailing invitations to distributors, physicians, hospital and government personnel to visit our booth. Visitors enjoyed the opportunity to learn about our company, our products and how we can help them meet the challenges of providing more cost-effective healthcare to a rapidly growing and aging patient population in their respective countries.
Bolstered by the inclusion, for the first time, of EECP® Therapy in the ESC guidelines on the management of stable coronary artery disease with a IIa class recommendation, we received a significant amount of new and renewed interest in EECP® Therapy. In the addenda to the writing committees, after they had reviewed the large volume of clinical literature regarding EECP® Therapy, stated, “The results of these studies proving the concept and clinical effects of EECP treatment lead to the recommendation that EECP Therapy should be considered for symptomatic treatment in patients with invalidating refractory angina.”
In addition, a poster, entitled the “Long-term clinical outcomes in patients with coronary artery disease and moderate angina pectoris treated with enhanced external counterpulsation” by Dr. Ozlem Soran, et al, from the University of Pittsburgh Medical, Pittsburg, PA, was presented in this year’s ESC annual meeting. In the abstract, the authors summarized the clinical benefits by stating that “Patients presenting for EECP treatment with class II angina had different baseline profiles compared with Class III and IV angina. However, both cohorts achieved substantial reduction in angina with high event free survival rates at 2 years.”
There was considerable interest shown by both cardiologists as well as the administrators of hospitals, clinics and private physician practices in the company’s latest offering, the MobiCare™ wireless vital signs patient monitor. The comprehensive monitoring features and the unique communications capabilities of MobiCare™ provide clinician with accurate patient information and optimal flexibility to view the patient’s vital signs remotely on a tablet or smart phone.
Supported by our colleagues from Biox as well as personnel from our European and Korean distributors, the exhibition booth, though very busy at times, was well covered and it soon became customary to hear at least three or four foreign languages spoken in the booth simultaneously.
During the exhibition we closed multiple sales deals, including the sale of the Lumenair™ EECP® Therapy system used for live demonstrations in the show right out of the booth.